AF
CRDF icon

Amalgamated Financial’s Cardiff Oncology CRDF Stock Holding History

Amalgamated Financial’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$11K Buy
+4,585
New +$16.2K ﹤0.01% 2873

Other funds holding CRDF

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Financial's CRDF Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Cardiff Oncology (CRDF) in Q1 2022: 4,585 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #2873 among its holdings.

91 funds tracked by Wall St. Rank hold CRDF as of Q1 2022.

  • Amalgamated Financial held 4,585 shares of Cardiff Oncology worth $11K as of Q1 2022.
  • Cardiff Oncology was a new Amalgamated Financial position in Q1 2022.
  • Cardiff Oncology made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2873 holding.
  • 91 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.